223 related articles for article (PubMed ID: 24898294)
1. Behavior of sartans (antihypertensive drugs) in wastewater treatment plants, their occurrence and risk for the aquatic environment.
Bayer A; Asner R; Schüssler W; Kopf W; Weiß K; Sengl M; Letzel M
Environ Sci Pollut Res Int; 2014 Sep; 21(18):10830-9. PubMed ID: 24898294
[TBL] [Abstract][Full Text] [Related]
2. LC-MS screening techniques for wastewater analysis and analytical data handling strategies: Sartans and their transformation products as an example.
Letzel T; Bayer A; Schulz W; Heermann A; Lucke T; Greco G; Grosse S; Schüssler W; Sengl M; Letzel M
Chemosphere; 2015 Oct; 137():198-206. PubMed ID: 26246044
[TBL] [Abstract][Full Text] [Related]
3. Selective determination of sartan drugs in environmental water samples by mixed-mode solid-phase extraction and liquid chromatography tandem mass spectrometry.
Castro G; Rodríguez I; Ramil M; Cela R
Chemosphere; 2019 Jun; 224():562-571. PubMed ID: 30836251
[TBL] [Abstract][Full Text] [Related]
4. Sartan blood pressure regulators in classical and biofilm wastewater treatment - Concentrations and metabolism.
Li R; Liang C; Svendsen SB; Kisielius V; Bester K
Water Res; 2023 Feb; 229():119352. PubMed ID: 36450176
[TBL] [Abstract][Full Text] [Related]
5. Separation and quantitation of several angiotensin II receptor antagonist drugs in human urine by a SPE-HPLC-DAD method.
Ferreirós N; Iriarte G; Alonso RM; Jiménez RM; Ortíz E
J Sep Sci; 2008 Mar; 31(4):667-76. PubMed ID: 18307163
[TBL] [Abstract][Full Text] [Related]
6. Identification and determination of selected angiotensin II receptor antagonist group drugs by HPLC method.
Czerwińska K; Mazurek AP
Acta Pol Pharm; 2011; 68(6):831-7. PubMed ID: 22125946
[TBL] [Abstract][Full Text] [Related]
7. Occurrence and fate of the angiotensin II receptor antagonist transformation product valsartan acid in the water cycle--a comparative study with selected β-blockers and the persistent anthropogenic wastewater indicators carbamazepine and acesulfame.
Nödler K; Hillebrand O; Idzik K; Strathmann M; Schiperski F; Zirlewagen J; Licha T
Water Res; 2013 Nov; 47(17):6650-9. PubMed ID: 24070867
[TBL] [Abstract][Full Text] [Related]
8. Secondary Effects of Hypochlorite Treatment on the Emerging Pollutant Candesartan: The Formation of Degradation Byproducts and Their Toxicological Profiles.
Luongo G; Saviano L; Libralato G; Guida M; Siciliano A; Previtera L; Di Fabio G; Zarrelli A
Molecules; 2021 Jun; 26(11):. PubMed ID: 34198752
[TBL] [Abstract][Full Text] [Related]
9. In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists.
Taavitsainen P; Kiukaanniemi K; Pelkonen O
Eur J Clin Pharmacol; 2000 May; 56(2):135-40. PubMed ID: 10877007
[TBL] [Abstract][Full Text] [Related]
10. Widespread occurrence of neuro-active pharmaceuticals and metabolites in 24 Minnesota rivers and wastewaters.
Writer JH; Ferrer I; Barber LB; Thurman EM
Sci Total Environ; 2013 Sep; 461-462():519-27. PubMed ID: 23751335
[TBL] [Abstract][Full Text] [Related]
11. The occurrence of antihistamines in sewage waters and in recipient rivers.
Kosonen J; Kronberg L
Environ Sci Pollut Res Int; 2009 Jul; 16(5):555-64. PubMed ID: 19337767
[TBL] [Abstract][Full Text] [Related]
12. HPLC method transfer study for simultaneous determination of seven angiotensin II receptor blockers.
Marghany KA; Abdelsalam RA; Haddad GM
J Sep Sci; 2020 Apr; 43(8):1398-1405. PubMed ID: 31991050
[TBL] [Abstract][Full Text] [Related]
13. Identification and characterization of potential impurities of valsartan, AT1 receptor antagonist.
Sampath A; Reddy AR; Yakambaram B; Thirupathi A; Prabhakar M; Reddy PP; Reddy VP
J Pharm Biomed Anal; 2009 Oct; 50(3):405-12. PubMed ID: 19560892
[TBL] [Abstract][Full Text] [Related]
14. Environmental exposure of pharmaceuticals and musk fragrances in the Somes River before and after upgrading the municipal wastewater treatment plant Cluj-Napoca, Romania.
Moldovan Z; Chira R; Alder AC
Environ Sci Pollut Res Int; 2009 Aug; 16 Suppl 1():S46-54. PubMed ID: 18972147
[TBL] [Abstract][Full Text] [Related]
15. Occurrence of selected pharmaceuticals in the principal sewage treatment plants in Rome (Italy) and in the receiving surface waters.
Patrolecco L; Capri S; Ademollo N
Environ Sci Pollut Res Int; 2015 Apr; 22(8):5864-76. PubMed ID: 25352396
[TBL] [Abstract][Full Text] [Related]
16. Application of capillary zone electrophoresis to the screening of some angiotensin II receptor antagonists.
González L; Akesolo U; Jiménez RM; Alonso RM
Electrophoresis; 2002 Jan; 23(2):223-9. PubMed ID: 11840527
[TBL] [Abstract][Full Text] [Related]
17. Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials.
Stumpe KO
Clin Ther; 2004; 26 Suppl A():A33-7. PubMed ID: 15291378
[TBL] [Abstract][Full Text] [Related]
18. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan.
Smith DH; Dubiel R; Jones M
Am J Cardiovasc Drugs; 2005; 5(1):41-50. PubMed ID: 15631537
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive investigation of a wide range of pharmaceuticals and personal care products in urban and hospital wastewaters in Greece.
Papageorgiou M; Zioris I; Danis T; Bikiaris D; Lambropoulou D
Sci Total Environ; 2019 Dec; 694():133565. PubMed ID: 31401503
[TBL] [Abstract][Full Text] [Related]
20. Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach.
Nixon RM; Müller E; Lowy A; Falvey H
Int J Clin Pract; 2009 May; 63(5):766-75. PubMed ID: 19392925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
